MY149492A - Immunoglobulins directed against nogo - Google Patents
Immunoglobulins directed against nogoInfo
- Publication number
- MY149492A MY149492A MYPI20082130A MYPI20082130A MY149492A MY 149492 A MY149492 A MY 149492A MY PI20082130 A MYPI20082130 A MY PI20082130A MY PI20082130 A MYPI20082130 A MY PI20082130A MY 149492 A MY149492 A MY 149492A
- Authority
- MY
- Malaysia
- Prior art keywords
- directed against
- immunoglobulins directed
- against nogo
- nogo
- immunoglobulins
- Prior art date
Links
- 108010077641 Nogo Proteins Proteins 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000010410 Nogo Proteins Human genes 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100029831 Reticulon-4 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0525662.3A GB0525662D0 (en) | 2005-12-16 | 2005-12-16 | Immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY149492A true MY149492A (en) | 2013-09-13 |
Family
ID=35736284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20082130A MY149492A (en) | 2005-12-16 | 2006-12-14 | Immunoglobulins directed against nogo |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8362208B2 (enExample) |
| EP (2) | EP1960429B1 (enExample) |
| JP (1) | JP5015949B2 (enExample) |
| KR (1) | KR101355118B1 (enExample) |
| CN (1) | CN101374863B (enExample) |
| AR (1) | AR057239A1 (enExample) |
| AU (1) | AU2006325228B2 (enExample) |
| BR (1) | BRPI0619855A2 (enExample) |
| CA (1) | CA2633501C (enExample) |
| CR (1) | CR10099A (enExample) |
| CY (1) | CY1113094T1 (enExample) |
| DK (1) | DK1960429T3 (enExample) |
| EA (1) | EA015536B1 (enExample) |
| ES (1) | ES2389380T3 (enExample) |
| GB (1) | GB0525662D0 (enExample) |
| HR (1) | HRP20120684T1 (enExample) |
| IL (1) | IL192086A0 (enExample) |
| JO (1) | JO2795B1 (enExample) |
| MA (1) | MA30041B1 (enExample) |
| MY (1) | MY149492A (enExample) |
| NO (1) | NO20082699L (enExample) |
| NZ (1) | NZ569143A (enExample) |
| PE (1) | PE20071099A1 (enExample) |
| PL (1) | PL1960429T3 (enExample) |
| PT (1) | PT1960429E (enExample) |
| SI (1) | SI1960429T1 (enExample) |
| TW (1) | TWI378940B (enExample) |
| UA (1) | UA96279C2 (enExample) |
| WO (1) | WO2007068750A2 (enExample) |
| ZA (2) | ZA200805111B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2207808T3 (pl) * | 2007-11-02 | 2013-11-29 | Novartis Ag | Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne |
| EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| UY31809A (es) | 2008-05-06 | 2009-12-14 | Glaxo Group Ltd | Encapsulación de agentes biológicamente activos |
| EP2323691A2 (en) * | 2008-07-11 | 2011-05-25 | Glaxo Group Limited | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| CA2876284A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| WO2018232144A1 (en) * | 2017-06-14 | 2018-12-20 | Monojul, Llc | High-affinity anti-human folate receptor beta antibodies and methods of use |
| WO2020250204A1 (ko) * | 2019-06-13 | 2020-12-17 | 프레스티지 바이오파마 피티이. 엘티디. | 신규 cthrc1에 특이적 항체 및 이의 용도 |
| BR112022006534A2 (pt) | 2019-10-24 | 2022-07-05 | Novago Therapeutics Ag | Anticorpos anti-nogo-a |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| CA3224517A1 (en) | 2021-06-17 | 2022-12-22 | Petmedix Ltd | Anti canine cd20 antibodies |
| JP2024542958A (ja) | 2021-10-21 | 2024-11-19 | ペットメディックス・リミテッド | Ｐ７５ｎｔｒの細胞外ドメインを含むタンパク質 |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| IL314314A (en) | 2022-02-09 | 2024-09-01 | Petmedix Ltd | Therapeutic antibodies |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
| GB202217993D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
| CN120712277A (zh) | 2023-02-09 | 2025-09-26 | 佩特迈迪有限公司 | 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| SK282721B6 (sk) | 1994-05-27 | 2002-11-06 | Smithkline Beecham S.P.A. | Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| CA2225691A1 (en) | 1995-06-27 | 1997-01-16 | Research Foundation Of Cuny, Hunter College | Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| DK1098972T3 (da) | 1998-07-22 | 2011-01-03 | Smithkline Beecham Ltd | Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor |
| ES2529196T3 (es) | 1998-11-06 | 2015-02-17 | University Of Zurich | Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas |
| FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| DE10338136A1 (de) | 2003-08-15 | 2005-03-24 | European Molecular Biology Laboratory | Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| EP2213684A3 (en) | 2003-12-22 | 2011-05-18 | Glaxo Group Limited | Nogo-a antibodies for the treatment of Alzheimer disease |
| AU2005207003C1 (en) * | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| WO2005097184A2 (en) * | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
-
2005
- 2005-12-16 GB GBGB0525662.3A patent/GB0525662D0/en not_active Ceased
-
2006
- 2006-12-14 EP EP06830633A patent/EP1960429B1/en active Active
- 2006-12-14 WO PCT/EP2006/069737 patent/WO2007068750A2/en not_active Ceased
- 2006-12-14 MY MYPI20082130A patent/MY149492A/en unknown
- 2006-12-14 HR HRP20120684TT patent/HRP20120684T1/hr unknown
- 2006-12-14 US US12/097,279 patent/US8362208B2/en not_active Expired - Fee Related
- 2006-12-14 CN CN2006800529521A patent/CN101374863B/zh not_active Expired - Fee Related
- 2006-12-14 TW TW095146890A patent/TWI378940B/zh not_active IP Right Cessation
- 2006-12-14 JP JP2008545009A patent/JP5015949B2/ja not_active Expired - Fee Related
- 2006-12-14 SI SI200631393T patent/SI1960429T1/sl unknown
- 2006-12-14 UA UAA200807663A patent/UA96279C2/ru unknown
- 2006-12-14 DK DK06830633.1T patent/DK1960429T3/da active
- 2006-12-14 CA CA2633501A patent/CA2633501C/en not_active Expired - Fee Related
- 2006-12-14 EA EA200801343A patent/EA015536B1/ru not_active IP Right Cessation
- 2006-12-14 NZ NZ569143A patent/NZ569143A/en not_active IP Right Cessation
- 2006-12-14 AU AU2006325228A patent/AU2006325228B2/en not_active Ceased
- 2006-12-14 KR KR1020087017348A patent/KR101355118B1/ko not_active Expired - Fee Related
- 2006-12-14 PT PT06830633T patent/PT1960429E/pt unknown
- 2006-12-14 BR BRPI0619855-4A patent/BRPI0619855A2/pt not_active IP Right Cessation
- 2006-12-14 PE PE2006001607A patent/PE20071099A1/es not_active Application Discontinuation
- 2006-12-14 ES ES06830633T patent/ES2389380T3/es active Active
- 2006-12-14 AR ARP060105524A patent/AR057239A1/es active IP Right Grant
- 2006-12-14 PL PL06830633T patent/PL1960429T3/pl unknown
- 2006-12-14 EP EP20100162457 patent/EP2228391A3/en not_active Withdrawn
- 2006-12-24 JO JO2006457A patent/JO2795B1/en active
-
2008
- 2008-06-11 NO NO20082699A patent/NO20082699L/no not_active Application Discontinuation
- 2008-06-11 MA MA31018A patent/MA30041B1/fr unknown
- 2008-06-11 ZA ZA200805111A patent/ZA200805111B/xx unknown
- 2008-06-12 IL IL192086A patent/IL192086A0/en not_active IP Right Cessation
- 2008-06-20 CR CR10099A patent/CR10099A/es unknown
-
2009
- 2009-09-04 ZA ZA200906162A patent/ZA200906162B/en unknown
-
2012
- 2012-09-05 CY CY20121100801T patent/CY1113094T1/el unknown
-
2013
- 2013-01-28 US US13/751,588 patent/US20130287781A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005061544A3 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
| WO2006058868A8 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| JO2576B1 (en) | Antibodies | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| TW200611702A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| ZA200706740B (en) | Quinazolinone T-type calcium channel antagonists | |
| WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists | |
| CY1113310T1 (el) | Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων | |
| ATE475651T1 (de) | Aryl-substituierte heterozyklen und ihre verwendung | |
| TW200628473A (en) | Novel heterocycles | |
| WO2006110447A3 (en) | Pyrimidine derivatives and their use in the treatment of cancer | |
| TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
| UA87851C2 (ru) | Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |